Pioneer Surgical Technology (PST) announced its acquisition of Angstrom Medica, Inc., headquartered in Woburn, MA. Angstrom is the first company to obtain Food and Drug Administration (FDA) approval for a nanotechnology device -- NanOss(TM). NanOss chemistries enable products that are highly osteoconductive and can remodel over time into human bone. NanOss has potential application in trauma, spine and general orthopaedic markets. Terms of the acquisition were not disclosed. Angstrom Medica, Inc. becomes a wholly-owned subsidiary of PST and is part of its orthobiologics division.
"Angstrom Medica and its innovative technology represent a strategic addition to the Pioneer family," said Matthew N. Songer, M.D., Chairman and CEO of PST. "This latest orthobiologic acquisition complements our mission by developing technology that empowers surgeons to restore patients to normal function with products and methods not currently available."
NanOss, like human bone, is made of hydroxyapatite crystals. By controlling the material at the nanocrystalline level the resulting compound can have the strength of established polymer surgical implants. According to Angstrom's CEO Edward Ahn, Ph.D., "This biomaterial provides an opportunity for changing orthopaedic technology by offering surgeons and their patients devices that have great strength upon implantation and may gradually be replaced by living human bone."
Also in 2007, PST acquired Encelle, Inc., a North Carolina firm that develops novel products for tissue regeneration including E-Matrix(TM), a sterile, injectable biopolymer designed to repair or regenerate diseased or damaged tissue.
Said Wesley McDermott, PST's Vice President for New Business Development, "The Angstrom acquisition further expands Pioneer's position and opportunity in a growing orthobiologic market."